Reuters logo
BRIEF-RTT Moleculardx Launches HIV-1, HBV and HCV drug resistance and genethink fully integrated system
April 11, 2017 / 10:03 PM / 7 months ago

BRIEF-RTT Moleculardx Launches HIV-1, HBV and HCV drug resistance and genethink fully integrated system

April 11 (Reuters) - RTT MolecularDX USA Inc:

* RTT Moleculardx launches HIV-1, HBV and HCV drug resistance and genethink fully integrated system

* RTT Moleculardx says is taking pre-orders on kits, with expected delivery in late spring

* RTT Moleculardx - intends to utilize former trugene platform for a “bridging” 510k fast track strategy making regulatory application in 2017 Source text for Eikon: Further

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below